Skip to main content

Table 1 displaying patient characteristics

From: [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma

  Variable Responder
(n = 12)
Non-Responder
(n = 5)
Sex Male 9 (75%) 1 (20%)
Female 3 (25%) 4 (80%)
Age (years) Mean ± SD 62 ± 5 70 ± 5
Tumour size cT1 0 (0%) 0 (0%)
cT2 3 (25%) 2 (40%)
cT3 1 (8%) 0 (0%)
cT4 8 (67%) 3 (60%)
Nodal status cN0 5 (42%) 1 (20%)
cN1 3 (25%) 2 (40%)
cN2 4 (33%) 2 (40%)
Metastasis cM0 6 (50%) 1 (20%)
cM1 6 (50%) 4 (80%)
CA19-9 (U/ml) Median 621 5044
IQR 665 1241
CEA (ng/ml) Median 3.3 38.0
IQR 2.7 25.5
First line chemotherapy FOLFIRINOX 7 (58%) 4 (80%)
gemcitabine based 5 (42%) 1 (20%)
  1. Statistical analyses were performed with a two-sided level of significance of p < 0.05